Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells

被引：0
|
作者：
Amjad Ali
Hema Unnikannan
Jasmin Shafarin
Khuloud Bajbouj
Jalal Taneera
Jibran Sualeh Muhammad
Haydar Hasan
Albert Salehi
Samir Awadallah
Mawieh Hamad
机构：
[1] University of Sharjah,Sharjah Institute for Medical Research
[2] University of Sharjah,Department of Basic Medical Sciences, College of Medicine
[3] University of Sharjah,Department of Clinical Nutrition and Dietetics, College of Health Sciences
[4] Lund University,Department of Clinical science, UMAS, Clinical Research Center
[5] University of Gothenburg,Department of Neuroscience and Physiology, Metabolic Research Unit
[6] University of Sharjah,Department of Medical Laboratory Sciences, College of Health Sciences
来源：
Endocrine | 2022年 / 76卷
关键词：
Metformin; PCSK9; HNF-1α; SREBP2; LDL-cholesterol; LDLR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [1] Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells
    Ali, Amjad
    Unnikannan, Hema
    Shafarin, Jasmin
    Bajbouj, Khuloud
    Taneera, Jalal
    Muhammad, Jibran Sualeh
    Hasan, Haydar
    Salehi, Albert
    Awadallah, Samir
    Hamad, Mawieh
    ENDOCRINE, 2022, 76 (03) : 543 - 557
  • [2] PRO-PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE9 (PCSK9) VARIANT DATABASE: PRELIMINARY ANALYSIS
    Leigh, S. E.
    Jakubcova, T.
    Whittall, R. A.
    Humphries, S. E.
    ATHEROSCLEROSIS, 2009, 207 (01) : E9 - E9
  • [3] Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
    Wierzbicki, Anthony S.
    Grant, Paul
    CLINICAL MEDICINE, 2016, 16 (04) : 353 - 357
  • [4] UPDATE AND ANALYSIS OF THE UCL PRO-PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE9 GENE (PCSK9) VARIANT DATABASE
    Leigh, S. E. A.
    Lee, Y. Ping
    Whittall, R. A.
    Dawson, N.
    Das, S.
    Martin, A. C. R.
    Orengo, C. A.
    Humphries, S. E.
    ATHEROSCLEROSIS, 2014, 235 (02) : E98 - E98
  • [5] Pro protein convertase subtilisin kexin type 9 (PCSK9) inhibitors Pharmacological review and update
    Corral, Pablo
    Suter, Agustina
    Rusconi, Alejandro
    Trigo, Leandro
    INSUFICIENCIA CARDIACA, 2016, 11 (03) : 122 - 129
  • [6] Loss of the association between plasma Pro-protein Convertase Subtilisin/Kexin type 9 (PCSK9) and LDL-apoB100 catabolism in type 2 diabetes
    Verges, B.
    Costet, P.
    Duvillard, L.
    Brindisi, M. -C.
    Krempf, M.
    Cariou, B.
    DIABETOLOGIA, 2010, 53
  • [7] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Affects Gene Expression Pathways Beyond Cholesterol Metabolism in Liver Cells
    Lan, Hong
    Pang, Ling
    Smith, Marsha M.
    Levitan, Diane
    Ding, Wei
    Liu, Li
    Shan, Lixin
    Shah, Vidhi V.
    Laverty, Maureen
    Arreaza, Gladys
    Zhang, Qing
    Murgolo, Nicholas J.
    Hernandez, Marco
    Greene, Jonathan R.
    Gustafson, Eric L.
    Bayne, Marvin L.
    Davis, Harry R.
    Hedrick, Joseph A.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2010, 224 (01) : 273 - 281
  • [8] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [9] LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
    Sabatel-Perez, F.
    Garcia-Ropero, A.
    Santos-Gallego, G.
    Zafar, M. Urooj
    Badimon, J. J.
    DRUGS OF TODAY, 2019, 55 (05) : 329 - 344
  • [10] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
12345